Patterns of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia

Journal of Psychiatric Research

Volumn 42, Issue 8, 2008, Pages 676-683

  Wehmeier, Peter M ^a   Kluge, Michael ^b   Schacht, Alexander ^a   Helsberg, Karin ^a   Schreiber, Wolfgang ^c   Schimmelmann, Benno G ^d   Lambert, Martin ^e  

^a Medical Department   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c Psychiatric Hospital   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Antipsychotics; QLS; Quality of life; Schizophrenia; Subjective well being; SWN K

Indexed keywords

CLOZAPINE; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT; PHYSICIAN; PRIORITY JOURNAL; QUALITY OF LIFE; SCHIZOPHRENIA;

ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; ATTITUDE TO HEALTH; FEMALE; HEALTH STATUS; HUMANS; MALE; PATIENT SATISFACTION; PHYSICIANS; PROBABILITY; QUALITY OF LIFE; QUESTIONNAIRES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 43049160943     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2007.07.005     Document Type: Article

References (40)

1. Cardoso C.S., Caiaffa W.T., Bandeira M., Siqueira A.L., Abreu M.N.S., and Fonseca J.O.P. Factors associated with low quality of life in schizophrenia. Cad Saúde Publica 21 (2005) 1338-1343
2. Caron J., Mercier C., Diaz P., and Martin A. Socio-demographic and clinical predictors of quality of life in patients with schizophrenia or schizo-affective disorder. Psychiatry Research 137 (2005) 203-213
3. Chassany O., Sagnier P., Marquis P., Fullerton S., Aaronson N., and for the European Regulatory Issues on Quality of Life Assessment Group. Patient-reported outcomes: The example of health-related quality of life: A European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Information Journal 36 (2002) 209-238
4. Concato J., Shah N., and Horwitz R.I. Randomized, controlled trials, observational studies, and the hierarchy of research designs. New England Journal of Medicine 342 (2000) 1887-1892
5. Csernansky J.G., and Schuchart E.K. Relapse and rehospitalization rates in patients with schizophrenia: Effects of second generation antipsychotics. CNS Drugs 6 (2002) 473-484
6. de Haan L., Weisfelt M., Dingemans P.M.A.J., Linszen D.H., and Wouters L. Psychometric properties of the Subjective Well-being under Neuroleptics scale and the Subjective Deficit Syndrome Scale. Psychopharmacology 162 (2002) 24-28
7. Dossenbach M., Arango-Davila C., Silva Ibarra H., Landa E., Aguilar J., Caro O., et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the International Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Journal of Clinical Psychiatry 66 (2005) 1021-1030
8. Fitzgerald P.B., Williams C.L., Corteling N., Filia S.L., Brewer K., Adams A., et al. Subject and observer-rated quality of life in schizophrenia. Acta Psychiatrica Scandinavica 103 (2001) 387-392
9. Gasquet I., Haro J.M., Novick D., Edgell E.T., Kennedy L., Lepine J.P., and on behalf of the SOHO Study Group. Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: Results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. International Clinical Psychopharmacology 20 (2005) 199-205
10. Gureje O., Miles W., Keks N., Grainger D., Lambert T., McGrath J., et al. Olanzapine vs. Risperidone in the management of schizophrenia: A randomized double-blind trial in Australia and New Zealand. Schizophrenia Research 61 (2003) 303-314
11. In: Guy W. (Ed). ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338 (1976), Department of Health, Education and Welfare, Washington, DC, US 218-222
12. Hamilton S.H., Edgell E.T., Revicki D.A., and Breier A. Functional outcomes in schizophrenia: A comparison of olanzapine and haloperidol in a European sample. International Journal of Clinical Psychopharmacology 15 (2000) 245-255
13. Heinrichs D.W., Hanlon T.E., and Carpenter W.T. The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 10 (1984) 388-398
14. Hofer A., Kemmler G., Ederm U., Edlinger M., Hummer M., and Fleischhacker W.W. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. Journal of Clinical Psychiatry 65 (2004) 932-939
15. Hofer A., Baumgartner S., Edlinger M., Hummer M., Kemmler G., Rettenbacher M.A., et al. Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects. European Psychiatry 20 (2005) 386-394
16. Jones P.B., Barnes T.R., Davies L., Dunn G., Lloyd H., Hayhurst K.P., et al. Randomized controlled trial of the effect on Quality of Life of second- vs. first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Studty (CUtLASS 1). Archives of General Psychiatry 63 (2006) 1079-1087
17. Karow A., Czekalla J., Dittmann R.W., Schacht A., Wagner T., Lambert M., et al. Association of subjective well-being, symptoms and side-effects with compliance after 12 months of treatment in schizophrenia. Journal of Clinical Psychiatry 68 (2007) 75-80
18. Karow A., Moritz S., Lambert M., Schoder S., and Krausz M. PANSS syndromes and quality of life in schizophrenia. Psychopathology 38 (2005) 320-326
19. Karow A., and Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology 162 (2002) 3-10
20. Kilian R., Dietrich S., Toumi M., and Angermeyer M.C. Quality of life in persons with schizophrenia in out-patient treatment with first- or second-generation antipsychotics. Acta Psychiatrica Scandinavica 110 (2004) 108-118
21. Kluge M., Wehmeier P.M., Dittmann R.W., Langer F., Czekalla J., Lehmann M., et al. A simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: changes in psychopathology and subjective well-being. Pharmacopsychiatry 38 (2005) 6-12
22. Lambert M., Schimmelmann B.G., Schacht A., Wagner T., Naber D., Karow A., et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. Journal of Clinical Psychiatry 67 (2006) 1690-1697
23. Malla A., and Payne J. First-episode psychosis: Psychopathology, quality of life, and functional outcome. Schizophrenia Bulletin 31 (2005) 650-671
24. 2 receptors: a PET study in schizophrenia. American Journal of Psychiatry 164 4 (2007) 630-637
25. Montes J.M., Ciudad A., Gascon J., Gomez J.C., and for the EFESO Study Group. Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study. Progress in Neuropsychopharmacology and Biological Psychiatry 27 (2003) 667-674
26. Naber D., Moritz S., Lambert M., Pajonk F.G., Holzbach R., Mass R., et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophrenia Research 50 (2001) 79-88
27. Naber D., Karow A., and Lambert M. Subjective well-being under neuroleptic treatment and its relevance for compliance. Acta Psychiatrica Scandinavica 427 Suppl (2005) 29-34
28. Naber D., Riedel M., Klimke A., Vorbach E.U., Lambert M., Kühn K.U., et al. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcomes in patients with schizophrenia. Acta Psychiatrica Scandinavica 111 (2005) 106-115
29. Norman R.M.G., Malla A.K., McLean T., Voruganti L.P.N., Cortese L., McIntosh E., et al. The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. Acta Psychiatrica Scandinavica 102 (2000) 303-309
30. Putzhammer A., Perfahl M., Pfeiff L., and Hajak G. Correlation of subjective well-being in schizophrenic patients with gait parameters, expert-rated motor disturbances, and psychopathological status. Pharmacopsychiatry 38 (2005) 132-138
31. Revicki D.A., Genduso L.A., Hamilton S.H., Ganoczy D., and Beasley C.M. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial. Quality of Life Research 8 (1999) 417-426
32. Ritsner M. Predicting changes in domain-specific quality of life of schizophrenia patients. Journal of Nervous and Mental Disease 191 (2003) 287-294
33. Ritsner M., and Gibel A. The effectiveness and predictors of response to antipsychotic agents to treat imapaired quality of life in schizophrenia: A 12-month naturalistic study with implications for confounding factors, antidepressants, anxiolytics, and mood stabilizers. Progress in Neuro-Psychopharmacology and Biological Psychiatry 30 (2006) 1442-1452
34. Ritsner M., Gibel A., Perelroyzen G., Kurs R., Jabarin M., and Ratner Y. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice. A naturalistic comparative study. Journal of Clinical Psychopharmacology 24 (2004) 582-591
35. Silva de Lima M., de Jesus Mari J., Breier A., Costa A.M., Pondé de Sena E., and Hotopf M. Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics. Journal of Clinical Psychiatry 66 (2005) 831-838
36. Voruganti L., Cortese L., Oyewumi L., Cernovsky Z., Zirul S., and Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophrenia Research 43 (2000) 135-145
37. Wehmeier P.M., Kluge M., Schacht A., Helsberg K., and Schreiber W. Correlation of physician and patient rated quality of life during antipsychotic treatment in out-patients with schizophrenia. Schizophrenia Research 91 (2007) 178-186
38. Wehmeier P.M., Kluge M., Schneider E., Schacht A., Wagner T., and Schreiber W. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 31 (2007) 703-712
39. Whitty P., Browne S., Clarke M., McTigue O., Waddington J., Kinsella T., et al. Systematic comparison of subjective and objective measures of quality of life at 4-year follow-up subsequent to a first episode of psychosis. Journal of Nervous and Mental Disease 192 (2004) 805-809
40. Zhang P.L., Santos J.M., Newcomer J., Pelfrey B.A., Johnson M.C., and de Erausquin G.A. Impact of atypical antipsychotics on quality of life, self-report of symptom severity, and demand of services in chronically psychotic patients. Schizophrenia Research 71 (2004) 137-144